Non-Coding RNAs in Prediabetes Beyond Glycemic Classification: Tissue Regulatory Networks, Progression Risk, and Intervention-Associated Dynamics
- 1Medical Course, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
- 2Department of Internal Medicine, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
- 3Department of Physiology, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
Abstract
Prediabetes can be readily identified using established glycemic tests, but these measures provide limited information about underlying molecular heterogeneity, future progression to type 2 diabetes mellitus (T2DM), or molecular responses to preventive interventions. This narrative review evaluates whether non-coding RNAs (ncRNAs) may provide complementary information beyond glycemic classification. We integrate evidence on microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), with brief consideration of emerging small ncRNA classes and epitranscriptomic regulation, emphasizing tissue-resolved regulatory crosstalk in skeletal muscle, liver, pancreatic β-cells, and adipose tissue while distinguishing direct human prediabetes evidence from mechanistic findings derived from related metabolic contexts. Circulating and extracellular-vesicle-associated ncRNAs are critically assessed according to diagnostic, prognostic, predictive, and pharmacodynamic functions. Particular attention is given to Diabetes Prevention Program analyses, in which baseline miRNA profiles were associated with incident T2DM and showed an exploratory treatment-by-biomarker interaction, while metformin exposure was associated with longitudinal changes in circulating miRNAs. Current evidence supports ncRNAs primarily as hypothesis-generating tools for mechanistic discovery and as candidate markers for progression risk and intervention-associated molecular dynamics, rather than replacements for established glycemic testing. Prospective validation is required to determine whether ncRNA profiling adds clinically meaningful information beyond conventional risk factors.
Related
- Macrophage interferon regulatory factor 7 aggravates the progression of metabolic dysfunction-associated steatohepatitis.
- Network based approach identifies miR ‐145‐3p as a central regulatory hub associated to the progression from localized to metastatic medullary thyroid carcinoma
- Unsupervised Classification of Wide-Field Swept-Source Optical Coherence Tomography Reveals Patterns Associated With Glaucoma Severity and Progression.
- Association and Incremental Discriminative Value of Four Estimated Muscle-Related Indices for Progression from Prediabetes to Type 2 Diabetes Mellitus: A Retrospective Cohort Study with up to 10 Years of Follow-Up
- Association of urine pH with the progression in the individuals with prediabetes: a population-based cohort study in China
BibTeX
@article{kim2026noncoding,
title = {{Non-Coding RNAs in Prediabetes Beyond Glycemic Classification: Tissue Regulatory Networks, Progression Risk, and Intervention-Associated Dynamics}},
author = {Zion Kim and Eun Yeong Ha and Jae-Hyung Park},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101472},
url = {https://www.mdpi.com/2218-273X/16/10/1472},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Non-Coding RNAs in Prediabetes Beyond Glycemic Classification: Tissue Regulatory Networks, Progression Risk, and Intervention-Associated Dynamics
AU - Zion Kim
AU - Eun Yeong Ha
AU - Jae-Hyung Park
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101472
UR - https://www.mdpi.com/2218-273X/16/10/1472
AB - Prediabetes can be readily identified using established glycemic tests, but these measures provide limited information about underlying molecular heterogeneity, future progression to type 2 diabetes mellitus (T2DM), or molecular responses to preventive interventions. This narrative review evaluates whether non-coding RNAs (ncRNAs) may provide complementary information beyond glycemic classification. We integrate evidence on microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), with brief consideration of emerging small ncRNA classes and epitranscriptomic regulation, emphasizing tissue-resolved regulatory crosstalk in skeletal muscle, liver, pancreatic β-cells, and adipose tissue while distinguishing direct human prediabetes evidence from mechanistic findings derived from related metabolic contexts. Circulating and extracellular-vesicle-associated ncRNAs are critically assessed according to diagnostic, prognostic, predictive, and pharmacodynamic functions. Particular attention is given to Diabetes Prevention Program analyses, in which baseline miRNA profiles were associated with incident T2DM and showed an exploratory treatment-by-biomarker interaction, while metformin exposure was associated with longitudinal changes in circulating miRNAs. Current evidence supports ncRNAs primarily as hypothesis-generating tools for mechanistic discovery and as candidate markers for progression risk and intervention-associated molecular dynamics, rather than replacements for established glycemic testing. Prospective validation is required to determine whether ncRNA profiling adds clinically meaningful information beyond conventional risk factors.
SN - 2218-273X
ER -